Domenico Russo
A5037637576- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Lymphoma Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- CAR-T cell therapy research
- Drug Transport and Resistance Mechanisms
- Neutropenia and Cancer Infections
- Multiple Myeloma Research and Treatments
- Hemoglobinopathies and Related Disorders
- Mesenchymal stem cell research
- Immunodeficiency and Autoimmune Disorders
- Immunotherapy and Immune Responses
- Periodontal Regeneration and Treatments
- Cytomegalovirus and herpesvirus research
- Antifungal resistance and susceptibility
- Bone Tissue Engineering Materials
- Protein Degradation and Inhibitors
- Monoclonal and Polyclonal Antibodies Research
- DNA Repair Mechanisms
- Platelet Disorders and Treatments
- Cancer therapeutics and mechanisms
University of Brescia
2016-2025
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2016-2025
University of Naples Federico II
2008-2024
Istituto Ortopedico Gaetano Pini
2024
University of Messina
2024
National Marrow Donor Program
2024
Regione Campania
2021
Brescia University
2005-2019
University of Bologna
2003-2018
Policlinico S.Orsola-Malpighi
2018
Several small studies on patients with COVID-19 and haematological malignancies are available showing a high mortality in this population. The Italian Hematology Alliance aimed to collect data from adult who required hospitalisation for COVID-19.This multicentre, retrospective, cohort study included (aged ≥18 years) diagnosis of WHO-defined malignancy admitted 66 hospitals between Feb 25 May 18, 2020, laboratory-confirmed symptomatic COVID-19. Data cutoff analysis was June 22, 2020. primary...
Epidemiologic investigation of invasive fungal diseases (IFDs) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be useful to identify subpopulations who might benefit from targeted treatment strategies. The Gruppo Italiano Trapianto Midollo Osseo (GITMO) prospectively registered data on 1858 consecutive patients undergoing allo-HSCT between 2008 and 2010. Logistic regression analysis was performed risk factors for proven/probable IFD (PP-IFD) during the early (days 0...
BACKGROUND Patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) frequently relapse on imatinib acquisition of BCR‐ABL kinase domain (KD) mutations. To analyze the changes that second‐generation tyrosine inhibitors (TKIs) have brought in mutation frequency and type, a database review was undertaken results all KD analyses performed authors' laboratory from January 2004 to 2013. METHODS Interrogation retrieved 450 272 patients Ph+ ALL. Prescreening samples...
Abstract Several papers authored by international experts have proposed recommendations on the management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these recommendations, survival CML patients has become very close to normal. The next, ambitious, step is bring as many possible into a condition treatment-free remission (TFR). Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA; Italian Group for Hematologic Diseases Adult) Working Party (WP) developed project aimed at...
Abstract The phase III study was designed to compare event‐free survival (EFS) after treosulfan‐based conditioning with a widely applied reduced‐intensity (RIC) busulfan regimen in older or comorbid patients acute myeloid leukemia (AML) myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT). A previously reported confirmatory interim analysis of the randomized clinical including 476 demonstrated statistically significant noninferiority for treosulfan...
A Deep Molecular Response (DMR), defined as a BCR::ABL1 transcript at levels ≤ 0.01% by RT-qPCR, is the prerequisite for successful interruption of treatment among patients with Chronic Myeloid Leukemia (CML). However, approximately 50% in Treatment-Free Remission (TFR) studies had to resume therapy after their rose above 0.1% threshold. To improve detection sensitivity and accuracy, can be analyzed using digital PCR (dPCR). dPCR increases 10–100 fold; however, its ability better select TFR...
ABSTRACT Chronic Myeloid Leukemia (CML) is characterized by the BCR::ABL1 fusion gene, driving uncontrolled myeloid cell proliferation. Furthermore, metabolic dysregulation contributes to disease progression. Despite efficacy of tyrosine kinase inhibitors (TKIs), unresolved clinical needs persist, necessitating refined preclinical models. This study compared responses three commonly used CML lines (K562, LAMA84, KCL22) five TKIs (imatinib, nilotinib, dasatinib, bosutinib, ponatinib) and a...
In patients with Myelofibrosis (MF) treated ruxolitinib (RUX), the response is unpredictable at therapy start. We retrospectively evaluated impact of clinical/laboratory factors on responses in 408 RUX according to prescribing obligations 18 Italian Hematology Centers. At 6 months, 114 out 327 (34.9%) evaluable achieved a spleen response. By multivariable Cox proportional hazard regression model, pre-treatment negatively correlating were: high/intermediate-2 IPSS risk (p=0.024), large...
Bone marrow and adipose tissue human mesenchymal stem cells were seeded in highly performing 3D gelatin–chitosan hybrid hydrogels of varying chitosan content the presence platelet lysate evaluated for their proliferation osteogenic differentiation. Both bone hydrogel 1 (chitosan 8.1%) or 2 14.9%) showed high levels viability (80%–90%), differentiation was significantly higher with compared to fetal bovine serum, particularly 1. Mineralization detected early, after 21 days culture, when used...
Abstract Treatment‐free remission (TFR) by tyrosine kinase inhibitors (TKI) discontinuation in patients with deep molecular response (DMR) is a paramount goal the current chronic myeloid leukemia (CML) therapeutic strategy. The best DMR level real‐time quantitative PCR (RT‐qPCR) for TKI still matter of debate. To compare accuracy digital (dPCR) and RT‐qPCR BCR‐ABL1 transcript levels detection, 142 CML were monitored median time 24 months. Digital detected transcripts undetectable cases. dPCR...